Credit Suisse 12/04/2010 1 Outperform $40.50 12.6%
With 18 months worth of clinical data about the potential use of IVIG in Alzheimer's disease soon to be reported the broker suggests investing in the company gives a free option over this potential.
While a low case with respect to any blue sky is most likely in its view the broker sees enough value in the stock to retain its Outperform rating. Target unchanged at $40.50.
Target price is $40.50 Current Price is $36.08 Difference: $4.42
If CSL meets the Credit Suisse target it will return approximately 12% (excluding dividends, fees and charges).
credit suisse - $40.50, page-48
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$309.52 |
Change
1.420(0.46%) |
Mkt cap ! $149.5B | |||
| Open | High | Low | Value | Volume |
| $307.00 | $309.75 | $306.70 | $145.9M | 481.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 796 | $309.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $309.53 | 304 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |